Our Pipeline
Currently, four Inhibrx programs are in ongoing clinical trials: three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency (AATD). Additionally, INBRX-121 is our newest preclinical program currently in cell line development.
The Candidates
Preclinical
Phase 1
Phase 2
Phase 3
INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three to four weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.
Learn more Phase 1 Trial
INBRX-109
Our Tetravalent DR5 Agonist
INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.
Learn more Phase 1 Trial
INBRX-106
Our Hexavalent OX40 Agonist
INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.
Learn more clinicaltrials.gov
INBRX-105
Our PD-L1 x 4-1BB Tetravalent Conditional Agonist
INBRX-105 is a tetravalent sdAb-based therapeutic candidate currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 is designed to agonize 4-1BB selectively in the presence of PD-L1.
Learn more clinicaltrials.gov
INBRX-121
Our NKp46 Targeted Detuned IL-2
INBRX-121 is the first program to be borne from our Molecular Targeted Cytokine (MTC) Platform, which combines our sdAb platform with a proprietary detuned cytokine to enable expansion of specific cell populations.
Learn more
Near-term Clinical Milestones

1. INBRX-101 (AATD) Start to potentially registration-enabling trial
2. INBRX-101 (GvHD) Trial initiations for aGvHD and cGvHD
3. INBRX-105 (PD-L1x41BB) Single agent and Keytruda combination update
4. INBRX-109 (DR5) Initial mesothelioma, Ewing sarcoma, pancreatic cancer, colorectal cancer and GIST combination study data
5. INBRX-121 (IL-2x) IND filing
6. INBRX-106 (OX40) Single agent and Keytruda combination update
7. INBRX-105 (PD-L1x41BB) Possible start to first potentially
8. INBRX-109 (DR5) Potentially registration-enabling Phase 2 Chondrosarcoma data